摘要
目的探讨宫颈鳞状细胞癌(SCC)患者病灶中zeste同源增强子2(EZH2)及p53蛋白的表达情况与临床分期及预后的关系。方法采用量子点荧光双重染色方法,检测中山大学附属第一医院2005年1月至2006年12月168例宫颈鳞状细胞癌组织病理切片中EZH2和p53蛋白的表达情况,分析这两种蛋白表达与宫颈癌患者临床分期、淋巴结转移、肿瘤复发、无进展生存期(PFS)、总生存期(OS)的关系。结果随着SCC分期的升高,EZH2和p53更多地出现共同表达,有淋巴结转移的病例组织中EZH2和p53蛋白共同表达阳性率显著高于无淋巴结转移的病例(P<0.05)。EZH2和p53蛋白共同表达阳性患者的PFS、OS均明显小于表达为阴性的患者(P<0.05)。结论 EZH2和p53蛋白在宫颈鳞状细胞癌病灶中的表达与其临床分期、淋巴结转移和预后相关。
Objective To investigate the expressions of Enhancer of zeste homolog 2 （EZH2） and p53 in cervical Squa- mous Ceil Carcinoma （SCC） and its potential significance in the pathogenesis of SCC. Methods The expression and distribution of EZH2 and p53 were determined with reference to clinicopathological features（ tumor staging, lymph node metastasis） and patient smwival（overall and disease-free survival）. 168 cervical SCC cases were collected for multiplexed quantum dot immunohistochemistry analysis. Results The expression of EZH2 and p53 in cervical cancer tissue was higher in a later stage. The rising differences between groups are statistically significant （ P 〈 0. 05）. In the SCC group, EZH2/p53 protein were highly expressed in the cases with lymph node metastasis （P 〈 0. 05 ）. The cases with high ex- pression of both EZH2 and p53 showed a poorer prognosis in overall survival and disease-fi＇ee survival （ P 〈 0. 05 ）. Con- clusion There was a close relationship between SCC tissue EZH2/p53 and tumor staging, lymph node metastasis and survival prognosis.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2013年第12期962-965,共4页
Chinese Journal of Practical Gynecology and Obstetrics
基金
中山大学5010研究计划项目(2007010)
广东省科技计划项目(2012B031800068)
关键词
zeste同源增强子2
P53蛋白
宫颈癌
量子点荧光双重染色
enhancer of zeste homolog 2
p53 protein
cervical cancer
nmhiplexed quantum dot immunohistochemistry a- nalysis
